UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy

PloS one, 2016-05, Vol.11 (5), p.e0155100-e0155100

2016

Volltextzugriff (PDF)

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.229-237

2011

Volltextzugriff (PDF)

Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States

PloS one, 2016-01, Vol.11 (1), p.e0147821-e0147821

2016

Volltextzugriff (PDF)

Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trial

BMC complementary and alternative medicine, 2012-01, Vol.12 (1), p.7, Article 7

2012

Volltextzugriff (PDF)

The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease

The New England journal of medicine, 2001-03, Vol.344 (11), p.824-831

2001

Volltextzugriff (PDF)

A pseudo-response approach to constructing confidence intervals for the subset of patients expected to benefit from a new treatment

Journal of the Royal Statistical Society Series C: Applied Statistics, 2024-03, Vol.73 (2), p.522-539

2024

Volltextzugriff (PDF)

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

Annals of internal medicine, 2001-03, Vol.134 (6), p.440

2001

Volltextzugriff (PDF)

Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV

BMJ open, 2013-08, Vol.3 (8), p.e003028

2013

Volltextzugriff (PDF)

T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen

The Journal of infectious diseases, 2005-04, Vol.191 (7), p.1155-1163

2005

Volltextzugriff (PDF)

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

AIDS (London), 2013-03, Vol.27 (6), p.939-950

2013

Volltextzugriff (PDF)

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

Journal of acquired immune deficiency syndromes (1999), 2012-05, Vol.60 (1), p.33-42

2012

Volltextzugriff (PDF)

Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial

BMC musculoskeletal disorders, 2010-03, Vol.11 (1), p.40-40, Article 40

2010

Volltextzugriff (PDF)

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study

AIDS (London), 2016-01, Vol.30 (2), p.251-259

2016

Volltextzugriff (PDF)

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment

AIDS care, 2016-03, Vol.28 (3), p.401-408

2016

Volltextzugriff (PDF)

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

AIDS (London), 2002-03, Vol.16 (4), p.579-588

2002

Volltextzugriff (PDF)

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1 : primary 24-week analysis

AIDS (London), 2007-03, Vol.21 (6), p.F1-F10

2007

Volltextzugriff (PDF)

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

BMC infectious diseases, 2005-04, Vol.5 (1), p.23-23, Article 23

2005

Volltextzugriff (PDF)

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial

AIDS (London), 2009-01, Vol.23 (3), p.423-426

2009

Volltextzugriff (PDF)

Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double-Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir)

Journal of clinical pharmacology, 2010-04, Vol.50 (4), p.392-400

2010

Volltextzugriff (PDF)

The ARTEMIS trial: once-daily darunavir/ritonavir in the management of treatment-naive, HIV-infected patients

HIV therapy, 2009-03, Vol.3 (2), p.121-133

Cohen, Calvin J

2009

Volltextzugriff (PDF)

Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids

The AIDS reader, 2005-09, Vol.15 (9), p.462

Cohen, Calvin J

2005

Volltextzugriff (PDF)

Antiretroviral Therapy: The “When to start” Debates

Clinical infectious diseases, 2004-12, Vol.39 (11), p.1705-1708

2004

Volltextzugriff (PDF)

Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen

Journal of acquired immune deficiency syndromes (1999), 2004-09, Vol.37 (1), p.1140-1146

2004

Volltextzugriff (PDF)

Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2007-06, Vol.6 (2), p.95-100

2007

Volltextzugriff (PDF)

Short‐term Safety and Tolerability of a Once‐Daily Fixed‐Dose Abacavir‐Lamivudine Combination versus Twice‐Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study

Pharmacotherapy, 2008-03, Vol.28 (3), p.314-322

2008

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(91)

Publikationsform

Artikel
(122)
Bücher
(9)
Reviews
(2)
Berichte
(1)

Sprache

Englisch
(134)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States

Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trial

The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease

A pseudo-response approach to constructing confidence intervals for the subset of patients expected to benefit from a new treatment

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV

T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1 : primary 24-week analysis

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial

Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double-Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir)

The ARTEMIS trial: once-daily darunavir/ritonavir in the management of treatment-naive, HIV-infected patients

Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids

Antiretroviral Therapy: The “When to start” Debates

Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen

Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients

Short‐term Safety and Tolerability of a Once‐Daily Fixed‐Dose Abacavir‐Lamivudine Combination versus Twice‐Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study

Suchergebnisse filtern